Veterinary Medicines

Vulketan 2.5 mg/g gel for horses

Authorised
  • Ketanserin tartrate
Download as PDF

Product identification

Medicine name:
Vulketan 2.5 mg/g gel for horses
VULKETAN 2,5 MG/G
Active substance:
  • Ketanserin tartrate
Target species:
  • Horse
Route of administration:
  • Topical use

Product details

Active substance and strength:
  • Ketanserin tartrate
    3.45
    milligram(s)
    /
    1.00
    gram(s)
Pharmaceutical form:
  • Gel
Withdrawal period by route of administration:
  • Topical use
    • Horse
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QD03AX90
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Italy
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Audevard
Marketing authorisation date:
Manufacturing sites for batch release:
  • Sanochemia Pharmazeutika AG
Responsible authority:
  • MdS
Authorisation number:
  • 104327
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0265/001
Concerned member states:
  • Austria
  • Denmark
  • Finland
  • France
  • Germany
  • Iceland
  • Italy
  • Luxembourg
  • Netherlands
  • Portugal
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Italian (PDF)
Published on: 3/06/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."